EMMA — Emmaus Life Sciences Income Statement
0.000.00%
Last trade - 00:00- $0.70m
- $30.25m
- $16.65m
- 23
- 88
- 25
- 42
Annual income statement for Emmaus Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K/A | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 23.2 | 20.6 | 18.4 | 29.6 | 16.7 |
| Cost of Revenue | |||||
| Gross Profit | 20.9 | 17.3 | 15.8 | 28.3 | 15.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 24.6 | 27.1 | 25.5 | 26.9 | 17.5 |
| Operating Profit | -1.46 | -6.49 | -7.09 | 2.72 | -0.862 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 0.973 | -15.9 | -10.6 | -3.79 | -6.42 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 1.35 | -15.9 | -10.6 | -3.73 | -6.45 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 1.35 | -15.9 | -10.6 | -3.73 | -6.45 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 1.35 | -15.9 | -10.6 | -3.73 | -6.45 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.047 | -0.319 | -0.208 | -0.06 | -0.113 |